These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31312795)

  • 1. Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
    Özmen V; Çakar B; Gökmen E; Özdoğan M; Güler N; Uras C; Ok E; Demircan O; Işıkdoğan A; Saip P
    Eur J Breast Health; 2019 Jul; 15(3):183-190. PubMed ID: 31312795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
    Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
    PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
    Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
    J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
    Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
    Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.
    Ozmen V; Atasoy A; Gokmen E; Ozdogan M; Guler N; Uras C; Ok E; Demircan O; Isikdogan A; Saip P
    Cureus; 2016 Mar; 8(3):e522. PubMed ID: 27081583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey.
    Özmen V; Atasoy A; Gökmen E; Özdoğan M; Güler N; Uras C; Ok E; Demircan O; Işıkkdoğan A; Cabioğlu N; Şen F; Saip P
    J Breast Health; 2016 Jul; 12(3):107-111. PubMed ID: 28331745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
    Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
    J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
    Browne IM; McLaughlin RA; Weadick CS; O'Sullivan S; McSorley LM; Hadi DK; Millen SJ; Higgins MJ; Crown JP; Prichard RS; McCartan DP; Hill AD; Connolly RM; Noonan SA; O'Mahony D; Murray C; O'Hanlon-Brown C; Hennessy BT; Quinn CM; Kelly CM; O'Reilly S; Morris PG; Walshe JM
    Breast Cancer Res Treat; 2024 Oct; ():. PubMed ID: 39365509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
    Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
    Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
    Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
    J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer.
    El Karak F; Rassy E; Bassil J; Awali M; Hanna C; Saroufim A; Nasr F; Farhat F; Kattan J; Ghosn M; Paulden M
    Gulf J Oncolog; 2021 Jan; 1(35):27-35. PubMed ID: 33716210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
    Kip M; Monteban H; Steuten L
    J Comp Eff Res; 2015 Sep; 4(5):433-45. PubMed ID: 25872415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
    Holt S; Bertelli G; Humphreys I; Valentine W; Durrani S; Pudney D; Rolles M; Moe M; Khawaja S; Sharaiha Y; Brinkworth E; Whelan S; Jones S; Bennett H; Phillips CJ
    Br J Cancer; 2013 Jun; 108(11):2250-8. PubMed ID: 23695023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget Impact of the Oncotype DX Breast Recurrence Score
    Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Radeck-Knorre S; Neubauer AS
    Breast Care (Basel); 2024 Feb; 19(1):27-33. PubMed ID: 38384494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
    Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.